Get the Stockscreener App
0.2174
0.91%
-0.002
Curanex Pharmaceuticals Inc stock is traded at $0.2174, with a volume of 162.25K.
It is down -0.91% in the last 24 hours and up +3.52% over the past month.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
See More
Previous Close:
$0.2194
Open:
$0.2162
24h Volume:
162.25K
Relative Volume:
1.91
Market Cap:
$6.17M
Revenue:
-
Net Income/Loss:
$-7.24M
P/E Ratio:
-0.8512
EPS:
-0.2554
Net Cash Flow:
$-11.29M
1W Performance:
+11.49%
1M Performance:
+3.52%
6M Performance:
-24.09%
1Y Performance:
+0.00%
1-Day Range:
$0.2162
$0.23
1-Week Range:
$0.1906
$0.2321
52-Week Range:
$0.1788
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Name
Curanex Pharmaceuticals Inc
Sector
Industry
Phone
718-673-6078
Address
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.2174 | 6.41M | 0 | -7.24M | -11.29M | -0.2554 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Curanex Pharmaceuticals Inc Stock (CURX) Latest News
Curanex Pharmaceuticals Inc Common Stock (NASDAQ: CURX) Stock Price, News & Analysis - Kalkine
Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary - TradingView
CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Curanex Pharmaceuticals (CURX) Jumps 7.33% to $0.20 as Buyers Defend Key Support ZonePrice Target - dars.gov.et
Curanex Pharmaceuticals (CURX) Advances 7.33% as Shares Approach Key Resistance at $0.21Dark Pool Prints - dars.gov.et
Curanex Pharmaceuticals Inc - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.183|Chg%:-0.005 - TradingKey
Curanex Pharmaceuticals Inc (CURX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Curanex Pharmaceuticals Inc (CURX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.205|Chg%:+0.014 - TradingKey
Curanex Pharmaceuticals Inc (CURX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Curanex Pharmaceuticals Inc (CURX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curanex Pharmaceuticals Inc (CURX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Curanex Pharmaceuticals Inc (CURX) Institutional Confidence - TradingKey
CURX|Curanex Pharmaceuticals Inc|Price:0.213|Chg%:+0.008 - tradingkey.com
Curanex Pharmaceuticals Inc (CURX) Cash Flow - TradingKey
Curanex Pharmaceuticals Inc (CURX) Balance Sheet - TradingKey
Curanex Pharmaceuticals Inc (CURX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- po-news-eg.net
Curanex Pharmaceuticals Inc Revenue Breakdown – NASDAQ:CURX - TradingView
CURX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Curanex Pharmaceuticals (CURX) Drops 5.73%: Critical Support at $0.20 in PlayChannel Breakout - dars.gov.et
Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23Cup and Handle - dars.gov.et
Curanex Pharmaceuticals (CURX) Edges Higher as Bulls Defend Key $0.26 Support LevelFactor Rotation - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's After-Market SessionGain Therapeutics (NASDAQ:GANX), BNB Plus - Benzinga
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Nigeria
Curanex (CURX) OKs 5.7M-share incentive plan and 1:10–1:50 reverse split - Stock Titan
Enterprise value to EBITDA forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to book forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to sales forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Price to earnings forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Enterprise value to revenue forward of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Number of shareholders of Curanex Pharmaceuticals Inc – NASDAQ:CURX - TradingView
Curanex Pharmaceuticals (NASDAQ: CURX) approves 5.7M‑share plan and 1:10–1:50 reverse split - Stock Titan
Curanex Pharmaceuticals Inc (CURX) Valuation: PE, PB & Fair Value Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curanex Stock Sinks Toward 31 Cents as Nasdaq Clock Ticks - Bez Kabli
Curanex Pharmaceuticals Inc (CURX) Sees Modest Gain as Shares Test Key LevelsTechnical Analysis Picks - The Legal Advocate
CURXCuranex Pharmaceuticals Inc Stock Price and Quote - Finviz
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - minichart.com.sg
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
Curanex Pharmaceuticals Inc Stock (CURX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):